Immunotherapy's hidden danger: study probes blood vessel damage
NCT ID NCT07535944
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will follow 200 cancer patients starting immune checkpoint inhibitors (ICIs) to see if these drugs stiffen the arteries. Researchers will measure pulse wave velocity before treatment, after 6-8 weeks, and at one year. The goal is to better understand vascular side effects like vasculitis and blood clots, which may become more common as ICI use grows.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Immune checkpoint inhibitors (ICIs) such as nivolumab, pembrolizumab, atezolizumab, ipilimumab, cemiplimab, and others
What this could lead to
If successful, this study could help doctors understand and monitor blood vessel problems caused by immunotherapy, leading to better safety guidelines.
What could go wrong
This is an early observational study with no treatment being tested. It only measures changes in artery stiffness, so it may not capture all vascular risks or lead to direct patient benefits.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VASCULAR COMPLICATIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU de ROUEN
Rouen, 76031, France
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact